{"id":476980,"date":"2026-02-16T00:00:00","date_gmt":"2026-02-16T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfop0001-2025-biopharma-dry-and-wet-age-related-macular-degeneration-landscape-forecast-disease-landscape-forecast-2\/"},"modified":"2026-03-31T10:23:28","modified_gmt":"2026-03-31T10:23:28","slug":"dlsfop0001-2026-biopharma-dry-and-wet-age-related-macular-degeneration-landscape-forecast-disease-landscape-forecast","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfop0001-2026-biopharma-dry-and-wet-age-related-macular-degeneration-landscape-forecast-disease-landscape-forecast\/","title":{"rendered":"Dry and Wet Age-Related Macular Degeneration &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p class=\"text-align-left\">Age-related macular degeneration (AMD) is a late-onset retinal disease that diminishes central visual acuity due to photoreceptor degeneration in the macula, leading to vision impairment and blindness. Wet AMD is treated with historical mainstays such as off-label Avastin and Eylea, as well as newer entrants to the market such as Roche \/ Chugai\u2019s Vabysmo and Regeneron \/ Bayer \/ Santen\u2019s Eylea HD. The wet AMD market will see further fragmentation with the introduction of emerging therapies, most of which aim to further extend treatment intervals. These include three gene therapies (i.e., Regenxbio \/ AbbVie\u2019s sura-vec [formerly ABBV-RGX-314], Adverum \/ Eli Lilly&#8217;s ixo-vec, and 4DMT \/ Otsuka&#8217;s 4D-150), and three long-acting TKIs (i.e., EyePoint Pharmaceutical&#8217;s Duravyu, Ocular Therapeutix&#8217;s Axpaxli, and Clearside Biomedical&#8217;s CLS-AX). By contrast, the management of geographic atrophy (GA) is currently limited to two complement system inhibitors in the United States, Apellis\u2019s Syfovre and Astellas\u2019s Izervay. Across other G7 markets, only Izervay secured approval in Japan in September 2025. We expect the launch of J&#038;J Innovative Medicine\u2019s gene therapy JNJ-1887, Annexon\u2019s vonaprument (formerly ANX007), and Stealth BioTherapeutics\u2019 elamipretide in the United States and Europe starting in 2027.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How will the wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> treatment algorithm change as newer products such as Vabysmo and Eylea HD gain traction? To what extent will they capitalize on the need for therapies with longer dosing intervals?<\/li>\n<li>How will biosimilars of Eylea impact market dynamics in the different geographies?<\/li>\n<li>How receptive are retinal specialists to novel gene therapy approaches, <abbr data-abbreviation-entity=\"4974\" title=\"tyrosine kinase inhibitor\">TKI<\/abbr>s, and to other emerging therapies for wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> and <abbr title=\"geographic atrophy\">GA<\/abbr>?<\/li>\n<li>What are U.S. retinal specialists\u2019 impressions of Syfovre and Izervay?<\/li>\n<\/ul>\n<p><b>Geography: <\/b>United States, EU5, Japan<\/p>\n<p><strong>Primary research:<\/strong> Country-specific interviews with thought-leading retinal specialists; survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology:<\/strong> Total prevalence of wet AMD and geographic atrophy (GA) by country, including diagnosed\/drug-treated populations<\/p>\n<p><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key dry and wet age-related macular degeneration therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<p><strong>Drug treatments<\/strong>: Coverage of key current and late-phase emerging therapies<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<p>\u00b7 Optimize your long-term disease and development strategy.<\/p>\n<p>\u00b7 Quantify market potential for your pipeline assets and those of your competitors.<\/p>\n<p>\u00b7 Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/p>\n<p>\u00b7 Gauge the commercial outlook and impact of key market events.<\/p>\n","protected":false},"template":"","class_list":["post-476980","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-age-related-macular-degeneration","biopharma-therapy-areas-ophthalmology","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/476980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/476980\/revisions"}],"predecessor-version":[{"id":575199,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/476980\/revisions\/575199"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=476980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}